| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | 0.017 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | JQ-1 | CTRPv2 | pan-cancer | AAC | 0.0037 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.004 | 0.9 |